XML 44 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment and Geographic Area Information Segment and Geographic Area Information
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
Substantially all of AbbVie's net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:
years ended December 31 (in millions)202120202019
Immunology
HumiraUnited States$17,330 $16,112 $14,864 
International3,364 3,720 4,305 
Total$20,694 $19,832 $19,169 
SkyriziUnited States$2,486 $1,385 $311 
International453 205 44 
Total$2,939 $1,590 $355 
RinvoqUnited States$1,271 $653 $47 
International380 78 — 
Total$1,651 $731 $47 
Hematologic Oncology
ImbruvicaUnited States$4,321 $4,305 $3,830 
Collaboration revenues1,087 1,009 844 
Total$5,408 $5,314 $4,674 
VenclextaUnited States$934 $804 $521 
International886 533 271 
Total$1,820 $1,337 $792 
Aesthetics
Botox Cosmetic (a)
United States$1,424 $687 $— 
International808 425 — 
Total$2,232 $1,112 $— 
Juvederm Collection (a)
United States$658 $318 $— 
International877 400 — 
Total$1,535 $718 $— 
Other Aesthetics (a)
United States$1,268 $666 $— 
International198 94 — 
Total$1,466 $760 $— 
Neuroscience
Botox Therapeutic (a)
United States$2,012 $1,155 $— 
International439 232 — 
Total$2,451 $1,387 $— 
Vraylar (a)
United States$1,728 $951 $— 
DuodopaUnited States$102 $103 $97 
International409 391 364 
Total$511 $494 $461 
Ubrelvy (a)
United States$552 $125 $— 
Other Neuroscience (a)
United States$667 $528 $— 
International18 11 — 
Total$685 $539 $— 
years ended December 31 (in millions)202120202019
Eye Care
Lumigan/Ganfort (a)
United States$273 $165 $— 
International306 213 — 
Total$579 $378 $— 
Alphagan/Combigan (a)
United States$373 $223 $— 
International156 103 — 
Total$529 $326 $— 
Restasis (a)
United States$1,234 $755 $— 
International56 32 — 
Total$1,290 $787 $— 
Other Eye Care (a)
United States$523 $305 $— 
International646 388 — 
Total$1,169 $693 $— 
Women's Health
Lo Loestrin (a)
United States$423 $346 $— 
International14 10 — 
Total$437 $356 $— 
Orilissa/OriahnnUnited States$139 $121 $91 
International6 4 2 
Total$145 $125 $93 
Other Women's Health (a)
United States$209 $181 $— 
International5 11 — 
Total$214 $192 $— 
Other Key Products
MavyretUnited States$754 $785 $1,473 
International956 1,045 1,420 
Total$1,710 $1,830 $2,893 
CreonUnited States$1,191 $1,114 $1,041 
LupronUnited States$604 $600 $720 
International179 152 167 
Total$783 $752 $887 
Linzess/Constella (a)
United States$1,006 $649 $— 
International32 18 — 
Total$1,038 $667 $— 
SynthroidUnited States$767 $771 $786 
All other$2,673 $2,923 $2,068 
Total net revenues$56,197 $45,804 $33,266 
(a)Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.
Net revenues to external customers by geographic area, based on product shipment destination, were as follows:
years ended December 31 (in millions)202120202019
United States$43,510 $34,879 $23,907 
Canada1,397 1,159 813 
Germany1,223 1,049 909 
Japan1,090 1,198 1,211 
France936 797 695 
China857 471 195 
Australia533 527 395 
Spain519 453 472 
Italy506 379 372 
United Kingdom497 509 372 
Brazil368 406 359 
All other countries4,761 3,977 3,566 
Total net revenues$56,197 $45,804 $33,266 
Long-lived assets, primarily net property and equipment, by geographic area were as follows:
as of December 31 (in millions)20212020
United States and Puerto Rico$3,369 $3,354 
Europe1,400 1,534 
All other341 360 
Total long-lived assets$5,110 $5,248